{"product_id":"venclexta","title":"Venetoclax","description":"\u003cp data-start=\"0\" data-end=\"164\"\u003e\u003cstrong data-start=\"0\" data-end=\"22\"\u003eActive Ingredient:\u003c\/strong\u003e Venetoclax\u003cbr data-start=\"33\" data-end=\"36\"\u003e\u003cstrong data-start=\"36\" data-end=\"45\"\u003eForm:\u003c\/strong\u003e Oral tablet\u003cbr data-start=\"57\" data-end=\"60\"\u003e\u003cstrong data-start=\"60\" data-end=\"75\"\u003eOriginal Brand Name:\u003c\/strong\u003e Venclexta\u003cbr data-start=\"85\" data-end=\"88\"\u003e\u003cstrong data-start=\"88\" data-end=\"105\"\u003eGeneric Name:\u003c\/strong\u003e Ventax\u003cbr data-start=\"112\" data-end=\"115\"\u003e\u003cstrong data-start=\"115\" data-end=\"140\"\u003eGeneric Manufacturer:\u003c\/strong\u003e Ziska Pharmaceuticals\u003c\/p\u003e\n\u003ch3 data-start=\"166\" data-end=\"436\"\u003e\u003cstrong data-start=\"166\" data-end=\"182\"\u003eIndications:\u003c\/strong\u003e\u003cbr data-start=\"182\" data-end=\"185\"\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/h3\u003e\n\u003cp data-start=\"166\" data-end=\"436\"\u003eVenetoclax is a targeted oral therapy jointly developed by AbbVie Inc. and Genentech (a member of the Roche Group). As a BCL-2 inhibitor, it promotes apoptosis (programmed cell death) in cancer cells and is FDA- and EMA-approved for the treatment of:\u003c\/p\u003e\n\u003cul data-start=\"437\" data-end=\"562\"\u003e\n\u003cli data-start=\"437\" data-end=\"475\"\u003e\n\u003cp data-start=\"439\" data-end=\"475\"\u003eChronic lymphocytic leukemia (CLL)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"476\" data-end=\"512\"\u003e\n\u003cp data-start=\"478\" data-end=\"512\"\u003eSmall lymphocytic lymphoma (SLL)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"513\" data-end=\"562\"\u003e\n\u003cp data-start=\"515\" data-end=\"562\"\u003eCertain types of acute myeloid leukemia (AML)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"564\" data-end=\"813\"\u003eSpecifically, \u003cmeta charset=\"utf-8\"\u003eVenetoclax is indicated as monotherapy for patients with CLL who have a 17p deletion or TP53 mutation and have failed treatment with a B-cell receptor pathway inhibitor, or for those who have failed both chemotherapy and BCR inhibitors.\u003c\/p\u003e\n\u003ch3 data-start=\"815\" data-end=\"1152\"\u003e\u003cstrong data-start=\"815\" data-end=\"845\"\u003eDosage and Administration:\u003c\/strong\u003e\u003cbr data-start=\"845\" data-end=\"848\"\u003e\u003c\/h3\u003e\n\u003cp data-start=\"815\" data-end=\"1152\"\u003eTreatment begins at 20 mg orally once daily and is gradually increased over 5 weeks to a target dose of 400 mg once daily. This dose ramp-up is designed to reduce the risk of tumor lysis syndrome (TLS). After reaching the maintenance dose, treatment continues until disease progression or intolerability.\u003c\/p\u003e\n\u003ch3 data-start=\"1154\" data-end=\"1360\"\u003e\u003cstrong data-start=\"1154\" data-end=\"1178\"\u003eCommon Side Effects:\u003c\/strong\u003e\u003cbr data-start=\"1178\" data-end=\"1181\"\u003e\u003c\/h3\u003e\n\u003cp data-start=\"1154\" data-end=\"1360\"\u003eNeutropenia, diarrhea, nausea, anemia, fatigue, and upper respiratory tract infection.\u003cbr data-start=\"1267\" data-end=\"1270\"\u003eSerious side effects may include pneumonia, febrile neutropenia, and tumor lysis syndrome.\u003c\/p\u003e\n\u003ch3 data-start=\"1362\" data-end=\"1476\"\u003e\u003cstrong data-start=\"1362\" data-end=\"1374\"\u003eStorage:\u003c\/strong\u003e\u003cbr data-start=\"1374\" data-end=\"1377\"\u003e\u003c\/h3\u003e\n\u003cp data-start=\"1362\" data-end=\"1476\"\u003eStore below 30°C in a cool, dry place, away from light and moisture. Keep out of reach of children.\u003c\/p\u003e\n\u003ch3 data-start=\"1478\" data-end=\"1508\"\u003e\u003cstrong data-start=\"1478\" data-end=\"1508\"\u003eFrequently Asked Questions\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp data-start=\"1688\" data-end=\"2049\"\u003e\u003cstrong data-start=\"1688\" data-end=\"1759\"\u003eQ: Is the \u003cmeta charset=\"utf-8\"\u003eVenetoclax sold by Mediva Rx the original brand-name drug?\u003c\/strong\u003e\u003cbr data-start=\"1759\" data-end=\"1762\"\u003eA: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic effect as the original, and is tested and approved by the Directorate General of Drug Administration (DGDA).\u003c\/p\u003e\n\u003cp data-start=\"2051\" data-end=\"2374\"\u003e\u003cstrong data-start=\"2051\" data-end=\"2120\"\u003eQ: Is the manufacturer of the \u003cmeta charset=\"utf-8\"\u003eVenetoclax generic version reliable?\u003c\/strong\u003e\u003cbr data-start=\"2120\" data-end=\"2123\"\u003eA: Yes. We work with Ziska Pharmaceuticals, one of the leading pharmaceutical manufacturers in Bangladesh, with in-house R\u0026amp;D, production, and quality control laboratories. The company is internationally GMP-certified. You can purchase with confidence.\u003c\/p\u003e\n\u003cp data-start=\"2376\" data-end=\"2867\"\u003e\u003cstrong data-start=\"2376\" data-end=\"2435\"\u003eQ: How does \u003cmeta charset=\"utf-8\"\u003eVenetoclax work, and who is it suitable for?\u003c\/strong\u003e\u003cbr data-start=\"2435\" data-end=\"2438\"\u003eA: \u003cmeta charset=\"utf-8\"\u003eVenetoclax is a BCL-2 inhibitor. BCL-2 is a protein that prevents cancer cells from undergoing apoptosis (natural cell death). By blocking BCL-2, the drug helps restore the self-destruct mechanism in cancer cells. It is most suitable for patients whose cancer involves this molecular target.\u0026nbsp;\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eDisclaimer:\u003c\/strong\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003cp\u003eThis information is for reference only. Specific treatment decisions should follow your physician’s instructions, the drug label, and the latest research.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003ePrescribing Information:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan style=\"font-family: 'Microsoft YaHei',sans-serif;\" lang=\"EN-US\"\u003e\u003ca title=\"藥品說明書\" href=\"https:\/\/www.ziskapharma.com.bd\/public\/storage\/product-files\/ventax-100-prescribing-information-139.pdf\"\u003e\u003cspan lang=\"EN-US\"\u003eDownload Link\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"Generic Venetoclax","offers":[{"title":"250mg (28 Tablets)","offer_id":45006246609095,"sku":"Ventax(250mg)","price":890.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/2463\/5335\/files\/ventax-100-169.jpg?v=1743961360","url":"https:\/\/karb8d-vb.myshopify.com\/products\/venclexta","provider":"藥神直送 Mediva Rx","version":"1.0","type":"link"}